Clinical trials
Completed Phase 3 Renal Insufficiency trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
103 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 3 |
| 2001 | 3 |
| 2002 | 2 |
| 2003 | 8 |
| 2004 | 5 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 2 |
| 2008 | 7 |
| 2009 | 7 |
| 2010 | 10 |
| 2011 | 6 |
| 2012 | 11 |
| 2013 | 5 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 103 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Astellas Pharma Inc | 6 |
| Scios, Inc. | 5 |
| Veloxis Pharmaceuticals | 5 |
| Akebia Therapeutics | 4 |
| Daiichi Sankyo Co., Ltd. | 4 |
| NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 3 |
| AbbVie | 2 |
| Amgen | 2 |
| AstraZeneca | 2 |
| Centre Hospitalier Universitaire, Amiens | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Renal Insufficiency | 103 |
| Renal Insufficiency, Chronic | 22 |
| Kidney Failure, Chronic | 19 |
| Heart Failure | 13 |
| Kidney Diseases | 13 |
| Anemia | 12 |
| Hyperphosphatemia | 11 |
| Diabetes Mellitus, Type 2 | 8 |
| Cardiomyopathies | 6 |
| Vitamin D Deficiency | 4 |
Trials
Showing 1 to 25 of 103. Each trial links to its page on Pharma Observatory.
3 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.